Compositions and methods using amino acid blends to provide health benefits in animals - Patents.com

A synergistic blend of glycine, methionine, cysteine, and glutamine addresses mitochondrial dysfunction and oxidative stress, improving health outcomes in aging populations by enhancing mitochondrial function and reducing stress-related diseases.

JP2024545404AInactive Publication Date: 2024-12-06SOCIETE DES PRODUITS NESTLE SA
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2024529377
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-02
Filing Date
2022-11-29
Publication Date
2024-12-06
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Aging is associated with mitochondrial dysfunction, oxidative stress, and various diseases, including neurodegenerative and metabolic disorders, for which existing treatments are inadequate.

Method used

A composition comprising a synergistic blend of glycine, methionine, cysteine, and glutamine, or their functional derivatives, is administered to improve mitochondrial function and reduce oxidative stress, thereby addressing the underlying causes of aging and related diseases.

Benefits of technology

The amino acid blend enhances mitochondrial respiration, reduces oxidative stress, and improves muscle and cognitive functions, slowing metabolic decline and maintaining overall health in middle-aged and elderly individuals.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024545404000006
    Figure 2024545404000006
  • Figure 2024545404000007
    Figure 2024545404000007
  • Figure 2024545404000008
    Figure 2024545404000008
Patent Text Reader

Abstract

Disclosed herein are compositions and methods relating to a synergistic blend of amino acids to provide health benefits to animals. The blend can include a synergistic combination of glycine, methionine, cysteine, and glutamine.
Need to check novelty before this filing date? Find Prior Art

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of and priority to U.S. Provisional Application No. 63 / 285,212, filed December 2, 2021, the disclosure of which is incorporated by reference in its entirety into this specification. [Background technology]

[0002] Population ageing has been a notable demographic event over the past few decades. Due to longer life spans, the middle-aged and elderly population has grown faster than the overall population, resulting in a large increase in their share of the rest of the population. For example, in the 1950s, one in every 12 people was aged 60 or over; by the end of the 2000s, one in every 10 people was aged 60 or over. It is projected that by the end of the 2050s, one in every five people worldwide will be aged 60 or over.

[0003] Mitochondrial dysfunction, oxidative stress, altered cell-cell communication (including chronic low-grade inflammation), genomic instability, telomere shortening, impaired proteostasis, altered nutrient sensing, altered epigenetics, and stem cell attrition have been proposed as hallmarks of aging. In addition, free radicals, i.e., reactive oxygen species (ROS), are a major contributor to aging by causing oxidative cell damage. Free radicals are necessary for many biochemical processes and are generated as by-products in some biochemical reactions or as substrates for other biochemical reactions in each cell. As mitochondria are the main source of intracellular reactive oxygen species (ROS), this hypothesis suggests a central role for mitochondria in normal mammalian aging. However, in recent years, many studies have questioned the importance of mitochondrial ROS in the aging process. Meanwhile, new evidence points to another facet of mitochondrial dysfunction that may suggest that mitochondria hold a key role at the heart of the complex and intricate processes that lead to cellular and organismal aging.

[0004] Furthermore, in humans, oxidative stress is involved in many diseases, including atherosclerosis, Parkinson's disease, heart failure, myocardial infarction, Alzheimer's disease, schizophrenia, bipolar disorder, fragile X syndrome, and chronic fatigue syndrome.

[0005] Oxidative stress contributes to tissue damage after UV irradiation and hyperoxia. This damage is believed to be important in neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and Huntington's disease. Oxidative stress is also thought to be related to certain cardiovascular diseases, since oxidation of low-density lipoprotein (LDL) in the vascular endothelium is a precursor to plaque formation. Oxidative stress also plays a role in the ischemic cascade that results from injury due to reperfusion of oxygen after hypoxia. This cascade includes both stroke and heart attack. Oxidative stress has also been implicated in chronic fatigue syndrome. Summary of the Invention

[0006] In a general embodiment, the present disclosure provides a composition comprising an effective amount of at least one glycine or functional derivative thereof in combination with at least one large neutral amino acid and / or cationic amino acid or precursor for use in the treatment or prevention in an individual of at least one physical condition selected from the group consisting of: i) a mitochondrial associated disease or a condition associated with altered mitochondrial function, and / or ii) oxidative stress or a condition associated with oxidative stress.

[0007] Another object of the present invention is to provide a composition comprising an effective amount of at least one glycine or a functional derivative thereof in combination with at least one large neutral amino acid and / or cationic amino acid or precursors thereof for use in delaying the onset of metabolic decline, maintaining muscle mass, reducing oxidative stress, maintaining immune function, and / or maintaining cognitive function in healthy middle-aged and older individuals.

[0008] It is a further object of the present invention to provide a composition comprising an effective amount of at least one glycine or a functional derivative thereof in combination with at least one large neutral amino acid and / or cationic amino acid or precursors thereof for use in i) mitigating the adverse effects of aging, ii) improving at least one of muscle performance or muscle recovery after exercise, athletic capacity and / or physical function, iii) reducing the severity of a metabolic and / or degenerative disease in an individual.

[0009] Another aspect of the invention relates to a method of preparing a composition for use according to the invention.

[0010] In one embodiment, the composition can include a synergistic blend of amino acids to provide a health benefit to an animal, the blend including a combination of glycine, methionine, cysteine, and glutamine.

[0011] In another embodiment, a method for providing a health benefit to an animal can include administering to the animal a synergistic blend of amino acids, the blend including a combination of glycine, methionine, cysteine, and glutamine.

[0012] Additional features and advantages are described herein, and will be apparent from the drawings and detailed description that follow. [Brief description of the drawings]

[0013] [Figure 1] FIG. 13 is a graph showing increased oxidative stress in PGC1A overexpressing fish during aging. Results are expressed as mean±SEM of n=3 experiments. Statistics were performed using two-way ANOVA with Tukey's multiple comparison test. *p<0.05, **p<0.01. [Diagram 2]Figure 1 shows that PGC1A overexpression and exercise increase the expression of amino acid transporters, particularly those involved in the transport of cationic amino acids (arginine, lysine, ornithine) and large neutral amino acids (leucine, isoleucine, valine, phenylalanine, tyrosine, tryptophan, methionine, histidine). Log2FC fold change of differentially expressed genes compared to lazy wild type (n=8 / group). [Diagram 3] Figure 1 shows that glycine, but not glucose, can restore mitochondrial respiration under acute oxidative stress conditions. Results represent O2 consumption of mitochondria isolated from skeletal muscle of zebrafish (n=3 per condition). Statistics were performed using two-way ANOVA in conjunction with Tukey's multiple comparison test. ***p<0.001, #p<0.05. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0014] [Definition] Some definitions are provided below, however definitions may be found in the "Embodiments" section below, and the heading "Definitions" above does not imply that such disclosure in the "Embodiments" section is not a definition.

[0015] All percentages stated herein are by total weight of the composition unless otherwise indicated. As used herein, "about," "approximately," and "substantially" are understood to refer to numbers within a certain range of numerical values, for example, within the range of -10% to +10% of the referenced number, preferably within the range of -5% to +5% of the referenced number, more preferably within the range of -1% to +1% of the referenced number, and most preferably within the range of -0.1% to +0.1% of the referenced number. All numerical ranges herein should be understood to include all integers or fractions within the range. Furthermore, these numerical ranges should be interpreted as supporting claims directed to any number or subset of numbers within the range. For example, a disclosure of 1 to 10 should be interpreted as corresponding to ranges of 1 to 8, 3 to 7, 1 to 9, 3.6 to 4.6, 3.5 to 9.9, etc.

[0016] As used in this disclosure and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context dictates otherwise. Thus, for example, reference to "a component" or "the component" includes two or more components.

[0017] The terms "comprise", "comprises", and "comprising" should be interpreted as inclusive rather than exclusive. Similarly, the terms "include", "including", and "or" should all be interpreted as inclusive unless such interpretation is clearly prevented by the context. However, the compositions disclosed herein may not include elements not specifically disclosed herein. Thus, disclosure of an embodiment using the term "comprising" includes disclosure of embodiments "consisting essentially of" and "consisting of" the specified component. A composition "consisting essentially of" means that the composition comprises at least 50% by weight of the referenced component, preferably at least 75% by weight of the referenced component, more preferably at least 85% by weight of the referenced component, and most preferably at least 95% by weight of the referenced component.

[0018] The term "and / or" used in the context of "X and / or Y" is interpreted as "X" or "Y" or "X and Y". Similarly, "at least one of X or Y" is interpreted as "X" or "Y" or "X and Y". As used herein, the terms "examples" and "for example", particularly when followed by a list of terms, are merely exemplary and illustrative and are not to be considered exclusive or inclusive. As used herein, a condition "associated with" or "linked with" another condition means that the conditions occur simultaneously, preferably that the conditions are caused by the same underlying condition, and most preferably that one of the specified conditions is caused by the other specified condition.

[0019] The terms "food," "food product," and "food composition" refer to a product or composition intended for consumption by an individual, such as a human, and providing at least one nutrient to such an individual. Food products typically contain at least one of protein, lipid, carbohydrate, and optionally one or more vitamins and minerals. The compositions of the present disclosure, including the many embodiments described herein, may comprise, consist of, or essentially comprise the elements disclosed herein, as well as any additional or optional ingredients, components, or elements described or not described herein that are useful in the diet.

[0020] An "oral nutritional supplement" or "ONS" is a composition that contains at least one macronutrient and / or at least one micronutrient, e.g., in a sterile liquid, semi-solid, or powder form, and is intended to supplement other nutritional intakes, such as nutritional intake from food. Non-limiting examples of commercially available ONS products include MERITENE®, BOOST®, NUTREN®, and SUSTAGEN®. In some embodiments, the ONS can be a liquid form of a beverage that can be consumed without the addition of additional liquid, e.g., the amount of liquid is one serving of the composition. When used in conjunction with "pet," the term refers to food formulated for companion animals.

[0021] As used herein, the term "glycine" includes precursors and functional derivatives.

[0022] As used herein, the term "methionine" includes precursors and functional derivatives. In one aspect, methionine can be L-methionine.

[0023] As used herein, the term "cysteine" includes precursors and functional derivatives. In one aspect, the cysteine ​​can be L-cysteine.

[0024] As used herein, the term "glutamine" includes precursors and functional derivatives. In one embodiment, glutamine can be L-glutamine.

[0025] As used herein, the term "precursor," when used in the context of amino acids, refers to any chemical that, when subjected to any chemical or biological process (e.g., when ingested by an animal), forms an amino acid. Precursors are typically found in plants or foods, but are not limited to such herein.

[0026] As used herein, the term "functional derivative," when used in the context of an amino acid, refers to any chemical that, when subjected to any chemical or biological process (e.g., when ingested by an animal), forms an amino acid. Functional derivatives are typically synthetic, but are not so limited herein.

[0027] As used herein, the term "isolated" means separated from one or more other compounds or components with which the compound may otherwise be found, e.g., as found in nature. Preferably, for example, "isolated" means that the specified compound is separated from at least a portion of the cellular material with which it is typically found in nature. In one embodiment, an isolated compound is pure, i.e., free of other compounds.

[0028] "Prevention" includes reducing the risk and / or severity of a condition or disease. The terms "treatment", "treat" and "to alleviate" include both prophylactic or preventive treatments (which prevent and / or delay the onset of the targeted condition or disorder) and curative, therapeutic or disease-modifying treatments, including therapeutic measures that cure, delay, attenuate the symptoms and / or halt the progression of a diagnosed condition or disease; as well as treatment of patients who are ill or diagnosed as suffering from a disease or medical condition, in addition to treatment of patients at risk of or suspected of having a disease. The terms do not necessarily imply that a subject is treated until cured. The terms "treatment" and "treat" also refer to maintaining and / or promoting the health of individuals who are not afflicted with a disease but who may be susceptible to an unhealthy condition. The terms "treatment / therapy", "treat / treat" and "alleviating" are also intended to include the synergistic or otherwise potentiating action of one or more primary preventative or therapeutic measures. The terms "treatment / therapy", "treat / treat" and "alleviating" are further intended to include the dietary management of a disease or condition, or dietary management for the prophylaxis or prevention of a disease or condition. Treatment may be patient-related or physician-related.

[0029] A "subject" or "individual" is a mammal, preferably a human. The term "elderly" in the human context means an age of at least 60 years, preferably greater than 63 years, more preferably greater than 65 years, and most preferably greater than 70 years. The term "older adult" in the human context means a postnatal age of 45 years or older, preferably greater than 50 years, more preferably greater than 55 years, and includes elderly people.

[0030] As used herein, an "effective amount" is an amount that prevents a deficiency, treats a disease or medical condition in an individual, or, more generally, alleviates the symptoms, manages the progression of a disease, or provides a nutritional, physiological, or medical benefit to the individual.

[0031] "Animal" includes mammals, including but not limited to rodents, aquatic mammals, domestic animals such as dogs, cats, and other pets, livestock such as sheep, pigs, cows, and horses, and humans. When "animal", "mammal", or plurals thereof are used, these terms also apply to any animal in which, depending on the context, a demonstrated or intended effect can be demonstrated, for example, by the animal benefiting from improved mitochondrial calcium transport. Although the term "individual" or "subject" is often used herein to refer to a human, the disclosure is not so limited. Thus, the term "individual" or "subject" refers to any animal, mammal, or human that can benefit from the methods and compositions disclosed herein.

[0032] As used herein, the term "regularly" refers to administration at least once a month, and in one aspect, at least once a week. In certain embodiments, more frequent administration or intake can be performed, such as two or three times a week. In one aspect, the dosing regimen can include intake at least once a day.

[0033] As used herein, the term "complete and balanced" when referring to a food composition means a food composition that contains all of the known necessary nutrients in appropriate amounts and proportions based on the recommendations of recognized authorities in the field of animal nutrition, and thus can serve as the sole source of dietary intake to sustain life or promote production without the need for additional nutritional sources. Nutritionally balanced pet food and animal feed compositions are known and widely available in the art, for example, complete and balanced food compositions formulated according to standards established by the Association of American Feed Control Officials (AAFCO). In one embodiment, "complete and balanced" may be in accordance with the current standards published by AAFCO on January 1, 2021.

[0034] As used herein, the term "companion animal" refers to domestic animals such as cats, dogs, rabbits, guinea pigs, ferrets, hamsters, mice, gerbils, horses, cows, goats, sheep, donkeys, and pigs. In one aspect, the companion animal may be a canine. In another aspect, the companion animal may be a feline.

[0035] As used herein, "neurodegenerative disease" or "neurodegenerative disorder" refers to any condition in the central nervous system that results in a gradual loss of functional neurons. In one embodiment, the neurodegenerative disease is associated with age-related cell death. Non-limiting examples of neurodegenerative diseases include Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (also known as ALS and Lou Gehrig's disease), AIDS encephalopathy, adrenoleukodystrophy, Alexander disease, Alper's syndrome, and the like. disease), ataxia-telangiectasia, Batten disease, bovine spongiform encephalopathy (BSE), Canavan disease, corticobasal degeneration, Creutzfeldt-Jakob disease, dementia with Lewy bodies, fatal familial insomnia, frontotemporal lobar degeneration, Kennedy disease, Krabbe disease, Lyme disease, Machado-Joseph disease, multiple sclerosis, multiple system atrophy, neuroacanthocytosis, Niemann-Pick disease, Pick's disease, primary lateral sclerosis, progressive supranuclear palsy, Refsum disease, Sandhoff disease, diffuse myelinating sclerosis, spinocerebellar ataxia, subacute combined spinal degeneration, tabes dorsalis, Tay-Sachs disease, toxic encephalopathy, transmissible spongiform encephalopathy, and wobbly hedgehog syndrome.

[0036] As used herein, "cognitive performance" refers to the degree to which a subject performs one or more cognitive functions well. As used herein, "cognitive function" refers to any mental process by which a person becomes aware of, perceives, or understands ideas. This function encompasses all aspects of perception, thinking, reasoning, and remembering, including, for example, perception, memory, attention, language comprehension, language expression, reading comprehension, mental recall, learning, and reasoning. Typically, cognitive function refers to at least memory.

[0037] Methods for measuring cognitive function are well known and can include, for example, individual tests or battery tests for any aspect of cognitive function. One such test is the Prudhoe Cognitive Function Test by Margallo-Lana et al. (2003) J. Intellect. Disability Res. 47:488-492. Another such test is the Mini Mental State Exam (MMSE), which is designed to assess orientation to time and place, memory, attention and calculation, recall, language use and comprehension, repetition, and complex commands. Folstein et al. (1975) J. Psych. Res. 12:189-198. Other tests useful for measuring cognitive function include the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) and the Cambridge Neuropsychological Test Automated Battery (CANTAB). Such tests can be used to objectively assess cognitive function so that changes in cognitive function can be measured and compared, for example in response to treatment with the methods disclosed herein.

[0038] As used herein, "cognitive disorder" refers to any condition that reduces cognitive function. Non-limiting examples of cognitive disorders include delirium, dementia, learning disabilities, attention deficit disorder (ADD), and attention deficit hyperactivity disorder (ADHD). "Stress-induced or stress-related cognitive dysfunction" refers to cognitive dysfunction that is induced by or related to stress.

[0039] Unless otherwise specified or clearly implied to the contrary by the stated context, any reference to a single feature or limitation of the invention is intended to include the corresponding multiple features or limitations, and any reference to multiple features or limitations is intended to include the corresponding single feature or single limitation.

[0040] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art.

[0041] [Embodiment] As detailed in the experimental data provided herein below, the inventors have found that the combination of compounds disclosed herein can support mitochondrial function in oxidative stress conditions such as aging, exercise, musculoskeletal disorders, respiratory disorders, pain syndromes, neurodegenerative disorders, and metabolic disorders. In particular, by reducing oxidative stress and improving mitochondrial function, the compositions of the present invention can, at least in combination, potentially enhance or synergize with each other's effects to treat, reduce the incidence, or reduce the severity of metabolic and degenerative disorders.

[0042] The reduction of oxidative stress and the improvement of mitochondrial function are mechanistically related. Mitochondrial dysfunction is associated with cellular damage, in part through reactive oxygen species (ROS) and metabolic abnormalities due to inability to metabolize nutrients, which in turn leads to metabolic and degenerative diseases. Without being bound by theory, the inventors have found that under conditions of oxidative stress, the requirement for cationic amino acids and large neutral amino acids increases. In particular, cationic amino acid transporters and large neutral amino acid transporters are overexpressed, suggesting that these amino acids are even more required to maintain mitochondrial function under high oxidative stress. Furthermore, glycine can restore mitochondrial respiration after acute oxidative stress.

[0043] An advantage of one or more embodiments provided by the present disclosure is to help off-set slowing of the metabolism associated with aging.

[0044] Yet another advantage of one or more embodiments provided by the present disclosure is that they provide important amino acids as energy fuel to mitochondria, thereby reducing the need to break down tissue proteins, including muscle proteins, to maintain sufficient cellular energy production.

[0045] Yet another advantage of one or more embodiments provided by the present disclosure is that it compensates for important amino acids that become unavailable in sufficient amounts in cells under conditions of oxidative stress.

[0046] Another advantage of one or more embodiments provided by the present disclosure is that they help reduce oxidative stress on the body.

[0047] The present disclosure provides compositions comprising an effective amount of a combination of at least one glycine or functional derivative thereof and at least one large neutral amino acid and / or cationic amino acid or precursor.

[0048] In one embodiment, the composition can include a synergistic blend of amino acids to provide a health benefit to an animal, the blend including a combination of glycine, methionine, cysteine, and glutamine.

[0049] In another embodiment, a method for providing a health benefit to an animal can include administering to the animal a synergistic blend of amino acids, the blend including a combination of glycine, methionine, cysteine, and glutamine.

[0050] In one embodiment, the at least one glycine or functional derivative thereof is selected from the group consisting of L-glycine, L-glycine ethyl ester, D-allylglycine, N-[bis(methylthio)methylene]glycine methyl ester, Boc-allyl-Gly-OH (dicyclohexylammonium) salt, Boc-D-Chg-OH, Boc-Chg-OH, (R)-N-Boc-(2'-chlorophenyl)glycine, Boc-L-cyclopropylglycine, Boc-L-cyclopropylglycine, (R)-N-Boc-4-fluorophenylglycine, Boc-D-propargylglycine, The glycine is selected from the group consisting of Boc-(S)-3-thienylglycine, Boc-(R)-3-thienylglycine, Da-cyclohexylglycine, La-cyclopropylglycine, N-(2-fluorophenyl)-N-(methylsulfonyl)glycine, N-(4-fluorophenyl)-N-(methylsulfonyl)glycine, Fmoc-N-(2,4-dimethoxybenzyl)-Gly-OH, N-(2-furoyl)glycine, La-neopentylglycine, D-propargylglycine, sarcosine, Za-phosphonoglycine trimethyl ester, and mixtures thereof.

[0051] In one embodiment, the cysteine ​​may be selected from the group consisting of L-cysteine, homocysteine, serine, and mixtures thereof.

[0052] In one embodiment, the glutamine may be selected from the group consisting of L-glutamine, glutamate, and mixtures thereof.

[0053] In one embodiment, the methionine may be selected from the group consisting of L-methionine, homoserine, serine, and mixtures thereof.

[0054] Non-limiting examples of suitable large neutral amino acids include leucine, isoleucine, valine, phenylalanine, tyrosine, tryptophan, threonine, methionine and histidine and mixtures thereof. Non-limiting examples of suitable cationic amino acids include arginine, lysine or ornithine. Precursors of the above amino acids may be advantageously used in the compositions of the present invention and are known in the art (see KEGG PATHWAY (www.genome.jp / kegg / pathway.html)).

[0055] The composition may comprise one or more of leucine, isoleucine, valine, phenylalanine, tyrosine, tryptophan, threonine, methionine and histidine in free form and / or bound to peptides and / or proteins, such as milk proteins, animal proteins or vegetable proteins.Whey protein is rich in BCAAs, such as leucine and isoleucine.Thus, some embodiments of the composition comprise whey protein, which provides at least a portion of the large neutral amino acids in the composition.

[0056] In another embodiment, known metabolic products of amino acids may be used, for example, 2-hydroxyisocaproic acid (HICA), a metabolic product of leucine, may be advantageously used.

[0057] In another embodiment, collagen and collagen peptides may be used as a source of glycine. Some plant-based protein sources may also provide a source of glycine.

[0058] Generally, for cats, glycine is present in a therapeutically effective amount to provide a health benefit to the cat. In one embodiment, glycine can be present in a composition formulated for cats in an amount of about 1% to about 15% by weight when fed. In another embodiment, glycine can be present in an amount of about 2% to about 10% by weight when fed.

[0059] Generally, for dogs, glycine is present in a therapeutically effective amount to provide health benefits to dogs. In one embodiment, glycine can be present in a composition formulated for dogs in an amount of about 0.5% to about 15% by weight when fed. In another embodiment, glycine can be present in an amount of about 1% to about 10% by weight when fed.

[0060] Generally, for cats, methionine is present in a therapeutically effective amount to provide a health benefit to the cat. In one embodiment, methionine can be present in a composition formulated for cats in an amount of about 0.2% to about 1.5% by weight when fed. In another embodiment, methionine can be present in an amount of about 0.5% to about 1% by weight when fed.

[0061] Generally, for dogs, methionine is present in a therapeutically effective amount to provide health benefits to dogs. In one embodiment, methionine can be present in a composition formulated for dogs in an amount of about 0.33% to about 5% by weight when fed. In another embodiment, methionine can be present in an amount of about 0.5% to about 2.5% by weight when fed.

[0062] Generally, for cats, cysteine ​​is present in a therapeutically effective amount to provide a health benefit to the cat. In one embodiment, cysteine ​​can be present in a composition formulated for cats in an amount of about 0.2% to about 10% by weight when fed. In another embodiment, cysteine ​​can be present in an amount of about 0.3% to about 5% by weight when fed.

[0063] Generally, for dogs, cysteine ​​is present in a therapeutically effective amount to provide a health benefit to the dog. In one embodiment, cysteine ​​can be present in a composition formulated for dogs in an amount of about 0.1% to about 10% by weight when fed. In another embodiment, cysteine ​​can be present in an amount of about 0.2% to about 5% by weight when fed.

[0064] Generally, for cats, glutamine (and / or glutamate) is present in a therapeutically effective amount to provide a health benefit to the cat. In one embodiment, glutamine (and / or glutamate) can be present in a composition formulated for cats in an amount of about 2% to about 30% by weight when fed. In another embodiment, glutamine (and / or glutamate) may be present in an amount of about 4% to about 20% by weight when fed.

[0065] Generally, for dogs, glutamine (and / or glutamate) is present in a therapeutically effective amount to provide a health benefit to the dog. In one embodiment, glutamine (and / or glutamate) can be present in a composition formulated for dogs in an amount of about 1% to about 30% by weight when fed. In another embodiment, glutamine (and / or glutamate) can be present in an amount of about 2% to about 15% by weight when fed.

[0066] A daily dose of the feline composition may include one or more of: about 125 mg to about 1.5 g of glycine per kg of body weight (bw); about 25 mg to about 1 g of cysteine ​​per kg of body weight; about 250 mg to about 5 g of glutamine (and / or glutamate) per kg of body weight; and about 25 mg to about 500 mg of methionine per kg of body weight.

[0067] A daily dose of the canine composition may include one or more of about 70 mg to about 2.25 g of glycine per kg of body weight (bw), about 14 mg to about 1.5 g of cysteine ​​per kg of body weight, about 140 mg to about 4.5 g of glutamine (and / or glutamate) per kg of body weight, and about 46 mg to about 750 mg of methionine per kg of body weight.

[0068] The daily dosage of the composition for other animals is 0.1-100 mg glycine per kg body weight (bw), 0.175-142.85 mg leucine per kg body weight, preferably 0.35-71.425 mg leucine per kg body weight; 0.175-71.425 mg isoleucine per kg body weight; 5-340 mg valine per kg body weight; 20-153 mg phenylalanine per kg body weight; 20-126 mg tyrosine per kg body weight; 2.8 mg phenylalanine per kg body weight; The composition may contain 6-42.86 mg tryptophan; 7-85 mg threonine per kg body weight; 3-43 mg methionine per kg body weight; 12.86-80 mg histidine per kg body weight; 20-300 mg arginine per kg body weight, preferably 50-200 mg arginine per kg body weight; 20-300 mg ornithine per kg body weight, preferably 100-200 mg ornithine per kg body weight; and 12-72 mg lysine per kg body weight. The daily dose of one or more large neutral or cationic amino acids may be provided by one or more servings of the composition per day. When several large neutral and / or cationic amino acids are combined in a composition, the minimum amount of each amino acid mentioned above may be reduced depending on the combination, and the maximum amount of each amino acid in the composition should not exceed the values ​​mentioned above.

[0069] In one embodiment, the at least one glycine or functional derivative thereof and the at least one large neutral amino acid and / or cationic amino acid or precursor are administered in the same composition.

[0070] In one embodiment, at least one glycine or functional derivative thereof and at least one large neutral amino acid and / or cationic amino acid or precursor are administered in a composition separate from the remainder of the combination.

[0071] Each compound can be administered simultaneously with the other compound (ie, as a single unit) or separated by fixed time intervals (ie, in separate units).

[0072] Raw Materials Further Bioactive Compounds The composition for use according to the invention may also comprise at least one further biologically active compound selected from the group consisting of antioxidants, anti-inflammatory compounds, glycosaminoglycans, prebiotics, fibres, probiotics, fatty acids, enzymes, minerals, trace elements and / or vitamins.

[0073] The term "bioactive" in the context of this application means that the compound contributes to the health of an individual or provides an effect to the human body beyond satisfying basic nutritional needs. At least one further bioactive compound may be of natural origin; that is, the compound may be obtained from an extract of a plant, animal, fish, fungus, algae, or microbial fermentation. Minerals are also considered to be of natural origin within this definition.

[0074] Nutritional composition The composition for use according to the invention may be a nutritional or pharmaceutical composition and may be for human or veterinary use. In one embodiment the combination is administered orally.

[0075] Thus, in a preferred embodiment, the composition for use according to the invention is a nutritional composition.

[0076] By "nutritional composition" is meant in the context of this application a composition that is a source of nutrition for an individual.

[0077] The nutritional formulation or composition of the present invention may be a complete or incomplete source of nutrition. As used herein, "complete nutrition" includes nutritional formulations and compositions that contain sufficient types and levels of macronutrients (protein, fat, and carbohydrate) and sufficient micronutrients to be the sole nutritional resource of the animal to which it is administered. A patient can obtain 100% of their nutritional needs from such a complete nutritional composition. As used herein, "incomplete nutrition" includes nutritional formulations or compositions that do not contain sufficient levels of macronutrients (protein, fat, and carbohydrate) or sufficient micronutrients to be the sole nutritional source of the animal to which it is administered. Partially complete or incomplete nutritional compositions can be used as dietary supplements.

[0078] Non-limiting examples of compositions suitable as these food compositions include dietary supplements, dietary supplements (e.g., liquid oral nutritional supplements (ONS), complete nutritional compositions, beverages, pharmaceuticals, oral nutritional supplements, medical foods, nutraceuticals, foods for special medical purposes (FSMP), powdered nutritional formulations to be reconstituted with water or milk prior to ingestion, food additives, medicines, drinks, pet foods, and combinations thereof.

[0079] In one embodiment, the composition for use according to the invention comprises a protein source. The protein source may be a food protein, including but not limited to animal protein (such as milk protein, meat protein, or egg protein), plant protein (such as soy protein, wheat protein, rice protein, and pea protein), or combinations thereof. In one embodiment, the protein is selected from the group consisting of whey, chicken, corn, caseinate, wheat, flax, soy, locust bean, pea, or combinations thereof.

[0080] In one embodiment, the composition comprises a carbohydrate source. Any suitable carbohydrate may be used in the composition of the present invention, including, but not limited to, starch, sucrose, lactose, glucose, fructose, corn syrup solids, maltodextrin, modified starch, amylose starch, tapioca starch, maize starch, xylitol, sorbitol, or combinations thereof.

[0081] In one embodiment, the composition comprises a fat source. The fat source can comprise any suitable fat or fat mixture. For example, the fat source can include, but is not limited to, vegetable fat (e.g., olive oil, corn oil, sunflower oil, high oleic sunflower oil, rapeseed oil, canola oil, hazelnut oil, soybean oil, palm oil, coconut oil, blackcurrant seed oil, borage oil, and lecithin), animal fat (e.g., dairy fat), or combinations thereof. The fat source can also be a crude product of the above fat (e.g., olive oil containing polyphenols).

[0082] In addition, compositions for use according to the invention may also include natural or artificial flavors, for example fruit flavors such as banana, orange, peach, pineapple or raspberry, or other botanical flavors such as vanilla, cocoa, coffee, etc.

[0083] Nutritional composition format In addition to the primary bioactive ingredient, and any further bioactive ingredients, and optionally one or more of a protein source, a carbohydrate source, and a fat source, the nutritional composition of the present invention may optionally contain any number of additional optional food ingredients, including conventional food additives (artificial or natural), such as, for example, one or more acidulants, additional thickeners, buffers or pH adjusters, chelating agents, colorants, emulsifiers, additives, flavorings, minerals, osmotic agents, pharma-ceutically acceptable carriers, preservatives, stabilizers, sugars, sweeteners, quality improvers, and / or vitamins. The optional ingredients may be added in any suitable amount.

[0084] The nutritional compositions of the present invention may be provided in any suitable format. Examples of nutritional composition formats in which the compositions for use according to the present invention may be provided include solutions, ready-for-consumption compositions (e.g., ready-to-drink compositions or instant beverages), liquid meals, soft drinks, juices, sports drinks, dairy drinks, milkshakes, yogurt drinks, soups, etc.

[0085] In another embodiment, the nutritional compositions of the present invention are provided in the form of concentrates, powders, or granules (e.g., effervescent granules) which may be diluted with water or other liquids such as milk or fruit juice to produce an instant composition.

[0086] Further formats of the nutritional compositions include baked products, dairy products, desserts, confectionery products, cereal bars, and breakfast cereals. Examples of dairy products include milk and milk products, yogurt and other cultured dairy products, ice cream, and cheese. Examples of baked products include bread, biscuits, and cakes.

[0087] In one embodiment, the composition for use according to the invention may also be available in a wide variety of formats designed as animal food, in particular for dogs or cats, whether in wet, semi-moist or dry form, in particular in the form of a biscuit.

[0088] The compositions disclosed herein may be used in any of a variety of formulations for therapeutic administration. More specifically, the pharmaceutical compositions may include suitable pharma-ceutically acceptable carriers or diluents and may be formulated as solid, semi-solid, liquid or gaseous formulations, such as tablets, capsules, powders, granules, ointments, liquids, suppositories, injections, inhalants, gels, microspheres and aerosols. Thus, administration of the compositions may be accomplished in a variety of ways, including oral, buccal, rectal, parenteral, intraperitoneal, intradermal, transdermal and intratracheal administration. The active ingredient may be systemic after administration or may be localized by the use of topical administration, intramural administration or the use of an implant that acts to retain an effective dose at the implantation site.

[0089] In pharmaceutical dosage forms, the compounds may be administered as pharma- ceutically acceptable salts. They may also be used in appropriate association with other pharmacologically active compounds. The following methods and additives are merely illustrative and in no way limiting.

[0090] In oral formulations, the compounds can be used alone or in combination with suitable excipients for the manufacture of tablets, powders, granules or capsules, e.g., in combination with conventional excipients such as lactose, mannitol, corn starch or potato starch, in combination with binders such as microcrystalline cellulose, functional derivatives of cellulose, gum arabic, corn starch or gelatin, in combination with disintegrating agents such as corn starch, potato starch or sodium carboxymethylcellulose, in combination with lubricants such as talc or magnesium stearate; and, if desired, in combination with diluents, buffers, wetting agents, preservatives and flavoring agents.

[0091] Pet food composition Generally, the pet food composition may include an amino acid blend of glycine, methionine, cysteine, and glutamine, and at least one of protein, carbohydrate, fat, and fiber.

[0092] Generally, the protein may be any crude protein material, including vegetable proteins such as soybean meal, soybean protein concentrate, corn gluten meal, wheat gluten, cottonseed, pea protein, canola meal and peanut meal, or animal proteins such as casein, albumin, and meat protein. Examples of meat proteins useful herein include beef, pork, lamb, horse, poultry, fish, and mixtures thereof. The composition may also optionally include other materials such as whey and other dairy by-products. In one aspect, the protein includes collagen, whey, or mixtures thereof. In one embodiment, the food composition may comprise protein in an amount from about 10%, 20%, 30%, 35%, 40%, 45%, 50% or even 55% by weight to about 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, or even 70% by weight, including various subranges within these amounts. In one aspect, the protein may be from about 20% to about 60% by weight of the food composition. In another aspect, the protein may be from about 25% to about 50% by weight of the food composition.

[0093] In addition, the composition can include isoflavones.In various embodiments, the isoflavones include at least one of daidzein, 6-O-malonyldaidzein, 6-O-acetyldaidzein, genistein, 6-O-malonylgenistein, 6-O-acetylgenistein, glycitein, 6-O-malonylglycitein, 6-O-acetylglycitein, biochanin A, or formononetin.In certain embodiments, the isoflavones or metabolites thereof can be derived from soybean (Glycine max).When present, the one or more metabolites preferably include equol. In one embodiment, the food composition may contain isoflavones in an amount of about 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg, or even 1,000 mg per kg of food composition, including various subranges within these amounts, up to about 500 mg; 600 mg; 700 mg; 800 mg; 900 mg; 1,000 mg; 1,100 mg; 1,200 mg; 1,300 mg; 1,400 mg; or even 1,500 mg per kg of food composition. In one aspect, the isoflavones may be present in an amount of about 300 mg to 1500 mg per kilogram of the pet food composition. In another aspect, the isoflavones may be present in an amount of about 700 mg to 1200 mg per kilogram of the pet food composition.

[0094] Generally, any type of carbohydrate can be used in the food composition. Examples of suitable carbohydrates include grains or cereals such as rice, corn, millet, sorghum, alfalfa, barley, soybean, canola, oats, wheat, rye, triticale, and mixtures thereof. In one embodiment, the carbohydrate comprises about 10% to about 70% by weight of the food composition. In another embodiment, the carbohydrate comprises about 20% to about 60% by weight of the food composition. In other aspects, the carbohydrate can be present in an amount of about 10%, 20%, 30%, 40%, or even 50% to about 20%, 30%, 40%, 50%, 60%, or even 70% by weight.

[0095] Generally, the food composition comprises fat. Examples of suitable fats include animal fats and vegetable fats. In one aspect, the fat source can be an animal fat source, such as tallow, lard, or poultry fat. Vegetable oils, such as corn oil, sunflower oil, safflower oil, grape seed oil, soybean oil, olive oil, fish oil, and other oils rich in monounsaturated fatty acids and n-6 ​​and n-3 polyunsaturated fatty acids can also be used. In one embodiment, the food composition can comprise fat in an amount of about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or even 50% by weight, including various subranges within these amounts, up to about 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, or even 60% by weight. In one embodiment, the fat comprises from about 10% to about 40% by weight of the food composition, hi another embodiment, the fat comprises from about 20% to about 35% by weight of the food composition.

[0096] In addition, the composition may include omega-3 fatty acids. Non-limiting examples of suitable omega-3 fatty acids include eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), alpha linolenic acid (ALA), and mixtures thereof. In one embodiment, the omega-3 fatty acids may range from about 0.2%, 0.5%, 1%, 2%, or even 3% to about 1%, 2%, 3%, 4%, or even 5% by weight of the composition. In some embodiments, the omega-3 fatty acids are present in the food composition in an amount of about 1% to about 5% by weight. In some embodiments, the omega-3 fatty acids are present in the food composition in an amount of about 1% to about 2% by weight.

[0097] In addition to the fats and fatty acids discussed herein, the composition may include omega-6 fatty acids. Non-limiting examples of suitable omega-6 fatty acids include linoleic acid (LA), gamma-linolenic acid (GLA), arachidonic acid (AA, ARA), eicosadienoic acid, docosadienoic acid, and mixtures thereof. In one embodiment, the omega-6 fatty acids may range from about 0.2%, 0.5%, 1%, 2%, or even 3% to about 1%, 2%, 3%, 4%, or even 5% by weight of the composition. In some embodiments, the omega-6 fatty acids are present in the food composition in an amount of about 1% to about 5% by weight. In some embodiments, the omega-6 fatty acids are present in the food composition in an amount of about 1% to about 2% by weight.

[0098] The administration of the pet food composition can be carried out periodically or intermittently, as needed and desired. In one aspect, the food composition can be administered to the animal periodically. In one aspect, administration can be at least once a week. In certain embodiments, more frequent administration or consumption can be carried out, such as twice or three times a week. In one aspect, the administration regimen can include at least one daily consumption.

[0099] According to the disclosed methods, administration can span the period from birth to adulthood of the animal, including administration as part of a dietary regimen. In various embodiments, the animal can be a human or a companion animal, such as a dog or cat. In certain embodiments, the animal can be a juvenile or growing animal. In other embodiments, administration can be on a regular or extended regular basis, beginning, for example, when the animal has reached more than about 10%, 20%, 30%, 40%, or 50% of its estimated or expected lifespan. In some embodiments, the animal may have reached 40%, 45%, or 50% of its expected lifespan. In still other embodiments, the animal may be older, having reached 60%, 66%, 70%, 75%, or 80% of its expected lifespan. Calculation of lifespan can be based on actuarial tables, calculations, estimates, or the like, and can take into account past, present, and future influences or factors known to positively or negatively affect lifespan. Considerations such as species, sex, body size, genetic factors, environmental factors and stressors, current and past health status, past and current nutritional status, and stressors may also have an impact and may be taken into account when calculating lifespan.

[0100] Such administration can be for a period of time necessary to achieve one or more of the objectives described herein, e.g., treatment of renal disease or treatment of cardiac disease. Other dosage amounts may be appropriate and can be determined based on the animal's initial weight, as well as other variables such as species, sex, breed, age, the desired health effect, etc.

[0101] The moisture content of the pet food composition varies depending on the nature of the food composition. The food composition may be a dry composition (e.g., kibble), a semi-moist composition, a moist composition, or any mixture thereof. In one embodiment, the composition may be a complete and nutritionally balanced pet food. In this embodiment, the pet food may be a "wet food", a "dry food", or a "medium moisture content" food. "Wet food" refers to pet food that is typically sold in cans or foil bags and has a moisture content that typically ranges from about 70% to about 90%. "Dry food" refers to pet food (typically in the form of small biscuit-like kibbles) that is similar in composition to wet food, but has a limited moisture content, typically ranging from about 5% to about 15% or 20%. In one embodiment, the composition may have a moisture content of about 5% to about 20%. Dry food products include a variety of foods with various moisture contents that are relatively shelf-stable and resistant to microbial or fungal deterioration or contamination. Also, in one aspect, the dry food composition may be an extruded food product for companion animals. In one embodiment, the pet food composition can be formulated for dogs, hi another embodiment, the pet food composition can be formulated for cats.

[0102] The food composition may also include one or more fiber sources. Such fiber sources include soluble, insoluble, fermentable, and non-fermentable fibers. Such fibers may be derived from plants, such as marine plants, but microbial fiber sources may also be used. As known to those skilled in the art, a variety of soluble or insoluble fibers may be used. The fiber source may be beet pulp (from sugar beet), gum arabic, gum talha, psyllium, rice bran, corn bran, wheat bran, oat bran, locust bean gum, citrus pulp, pectin, fructooligosaccharides, short chain oligofructose, mannan oligofructose, soybean fiber, arabinogalactan, galactooligosaccharides, arabinoxylan, cellulose, or mixtures thereof.

[0103] Alternatively, the fiber source may be fermentable fiber. Fermentable fiber has been previously reported to be beneficial to the immune system of companion animals. Fermentable fiber or other compositions known to those skilled in the art that provide prebiotics and promote the growth of probiotics in the intestine may also be incorporated into the composition to help enhance the effects described herein or to help enhance the effect on the immune system of animals.

[0104] In one embodiment, the food composition may include about 1% to about 15% total dietary fiber by weight. In some aspects, the total dietary fiber may be included in an amount of about 5% to about 15% by weight, or even about 8% to about 13% by weight. In another embodiment, the food composition may include about 1% to about 10% crude fiber by weight. In some aspects, the crude fiber may be included in an amount of about 3% to about 10% by weight, or even about 3% to about 7% by weight.

[0105] In some embodiments, the ash content of the food composition ranges from less than 1% to about 15%. In one aspect, the ash content may be from about 5% to about 10%.

[0106] Generally, the food composition may be a meal, a meal component, a snack, a supplement, or a treat. Such compositions may include complete foods intended to provide the necessary dietary requirements for an animal.

[0107] The pet food composition may further comprise one or more substances such as vitamins, minerals, antioxidants, probiotics, prebiotics, salts, and functional additives such as palatants, colorants, emulsifiers, and antimicrobials or other preservatives. Minerals that may be useful in such compositions include, for example, calcium, phosphorus, potassium, sodium, iron, chloride, boron, copper, zinc, magnesium, manganese, iodine, and selenium. Examples of additional vitamins useful herein include fat-soluble vitamins such as vitamin A, vitamin D, vitamin E, and vitamin K, and water-soluble vitamins including vitamin B and vitamin C. Inulin, amino acids, enzymes, coenzymes, and the like may be useful to include in various embodiments.

[0108] Route of administration The nutritional composition of the present disclosure may be administered by any method suitable for administration to humans, particularly to any part of the digestive tract. Enteral administration, oral administration, and administration through a tube or catheter are all included in the present disclosure. The nutritional composition of the present invention may also be administered by a method selected from oral, enteral, sublingual, sublabial, buccal, topical, etc.

[0109] The nutritional composition of the present invention may be administered in any convenient dosage form, including, for example, tablets, capsules, liquids, chewables, softgels, sachets, powders, syrups, suspensions, emulsions, and solutions. In soft capsules, the active ingredients are preferably dissolved or suspended in a suitable liquid, such as fatty oils, paraffin oil, or liquid polyethylene glycol. If desired, stabilizers may be added.

[0110] When the nutritional composition of the present invention is administered by tube feeding, the nutritional composition may be used for short-term tube feeding or long-term tube feeding.

[0111] The compositions of the invention can be administered to an individual, such as a human, for example an elderly or critically ill individual, in a therapeutically effective dose. The therapeutically effective dose can be determined by one of skill in the art and can vary depending on a number of factors known to those of skill in the art, such as the severity of the condition and the weight and general condition of the individual.

[0112] The compositions of the present invention are preferably administered to an individual at least one day per week, preferably at least two days per week, more preferably at least three days per week, most preferably seven days per week; at least one week, at least one month, at least two months, at least three months, at least six months, or even longer. In some embodiments, the compositions of the present invention are administered to an individual continuously for several days, for example, at least until a therapeutic effect is achieved. In some embodiments, the compositions of the present invention can be administered to an individual daily for at least 30, 60, or 90 consecutive days.

[0113] In some embodiments, administration continues for the remainder of the individual's life. In other embodiments, administration occurs until there is no detectable symptom of the medical condition. In specific embodiments, administration occurs until there is a detectable improvement in at least one symptom, and in further cases, administration continues to maintain remission.

[0114] The above dosing examples do not require uninterrupted daily administration. Rather, there may be several short interruptions in administration, such as a 2-4 day break during the administration period. The ideal duration of administration of the compositions of the present invention can be determined by one of skill in the art.

[0115] Treatment method Mitochondrial diseases are the result of either inherited or spontaneous mutations in mitochondrial or nuclear DNA, which alter the function of proteins or RNA molecules normally present in mitochondria. However, problems in mitochondrial function may only affect certain tissues due to factors occurring during development and growth that are not yet fully understood. Even when considering tissue-specific isoforms of mitochondrial proteins, it is difficult to explain the variable patterns of organ systems affected in clinical mitochondrial disease syndromes.

[0116] Mitochondrial diseases result from damage to mitochondria, specialized compartments present in all cells of the body except red blood cells. Mitochondria are responsible for producing over 90% of the energy the body needs to sustain life and support development. When mitochondria stop functioning, less energy is produced in cells. The cells become damaged and even die. When this process is repeated throughout the body, the whole system begins to break down, which severely threatens the person's life. Mitochondrial diseases primarily affect children, but adult onset is also becoming evident. Mitochondrial diseases appear to cause the most damage to cells of the brain, heart, liver, skeletal muscles, kidneys, and the endocrine and respiratory systems.

[0117] Many symptoms of mitochondrial disorders are non-specific. Symptoms may also show a temporary course with periodic worsening. Review articles on mitochondrial medicine mention episodic migraine states, as well as myalgia, gastrointestinal symptoms, tinnitus, depression, chronic fatigue, and diabetes among the various manifestations of mitochondrial disorders (Chinnery and Turnbull (1997) QJM 90:657-67; Finsterer (2004) Eur. J. Neurol. 11:163-86). In patients with mitochondrial disorders, clinical symptoms typically occur when energy demands are high in association with physiological stressors such as illness, hunger, excessive exercise, and extreme environmental temperatures. In addition, psychological stressors often trigger symptoms, probably due to the brain's energy demands being so high that the patient cannot perform sufficient ATP production.

[0118] Depending on which cells are affected, symptoms can include loss of motor control, muscle weakness and pain, gastrointestinal problems and difficulty swallowing, poor growth, heart disease, liver disease, diabetes, respiratory complications, seizures, visual / hearing problems, lactic acidosis, developmental delays, and increased susceptibility to infections.

[0119] Mitochondrial disorders include, but are not limited to, Alpers syndrome, Barth syndrome, beta-oxidation disorders, carnitine deficiency, carnitine-acyl-carnitine deficiency, chronic progressive external ophthalmoplegia syndrome, coenzyme Q10 deficiency, complex I deficiency, complex II deficiency, complex III deficiency, complex IV deficiency, complex V deficiency, CPT I deficiency, CPT II deficiency, creatine deficiency syndrome, cytochrome c oxidase deficiency, glutaric aciduria type 2, Kearns-Sayre syndrome, lactic acidosis, LCHAD (long-chain acyl-CoA dehydrogenase deficiency), Leber's hereditary optic neuropathy, Leigh syndrome, lethal infantile cardiomyopathy, cardiomyopathy, Luft's disease, MAD (medium-chain acyl-CoA dehydrogenase deficiency), mitochondrial cytopathy, mitochondrial DNA depletion, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like symptoms, mitochondrial encephalopathy, mitochondrial myopathy, mitochondrial recessive ataxia syndrome, muscular dystrophies, myoclonic epilepsy and ragged-red fiber disease, myoneurogenic gastrointestinal encephalopathy, neuropathy, ataxia, retinitis pigmentosa, and ptosis, Pearson's syndrome, POLG mutations, pyruvate carboxylase deficiency, pyruvate dehydrogenase deficiency, SCHAD (short-chain acyl-CoA dehydrogenase deficiency), and very long-chain acyl-CoA dehydrogenase deficiency.

[0120] Thus, one aspect of the present disclosure is a composition comprising an effective amount of at least one glycine or a functional derivative thereof in combination with at least one large neutral amino acid and / or cationic amino acid or precursors thereof for use in the treatment and / or prevention in an individual of at least one physical condition selected from the group consisting of: i) a mitochondrial-associated disease or a condition associated with altered mitochondrial function, and / or ii) oxidative stress or a condition associated with oxidative stress.

[0121] In one embodiment, the amount of the combination may be effective to treat or prevent a mitochondrial associated disease or condition selected from the group consisting of stress, obesity, reduced metabolic rate, metabolic syndrome, diabetes mellitus, diabetic complications, cardiovascular disease, respiratory disease, pain syndrome, hyperlipidemia, neurodegenerative disease, cognitive impairment, stress-induced or stress-related cognitive dysfunction, mood disorder, anxiety disorder, age-related neuronal cell death or dysfunction, musculoskeletal disorder, sarcopenia, frailty, pre-frailty, chronic kidney disease, macular degeneration, and combinations thereof.

[0122] In one embodiment, the at least one physical condition is selected from the group consisting of adverse effects of aging, muscle loss, prediabetes, gestational diabetes, type I diabetes, type II diabetes, diabetic complications, insulin resistance, metabolic syndrome, dyslipidemia, overweight, obesity, elevated cholesterol levels, elevated triglycerides, elevated fatty acids, fatty liver disease, renal disease, cardiovascular disease, musculoskeletal disease, respiratory disease, pain syndromes, neurodegenerative diseases, cognitive impairment, myopathy such as statin-induced myopathy, non-alcoholic steatohepatitis, tinnitus, dizziness, alcohol hangover, hearing loss, osteoporosis, high blood pressure, atherosclerosis / coronary artery disease, myocardial injury following stress, traumatic brain injury, cystic fibrosis, inflammation, cancer, and HIV infection.

[0123] In another embodiment, the present disclosure provides a method of slowing NAFLD, slowing HIV, combating the effects of aging, initiating metabolic decline, preserving muscle mass, reducing oxidative stress, preserving immune function, and / or preserving cognitive function in healthy middle-aged and elderly individuals. The healthy middle-aged and elderly individuals may be elderly.

[0124] In another embodiment, the present disclosure provides a method of enhancing reactive oxygen species metabolism, improving glucose regulation, and / or improving muscle function in an individual having at least one of obesity, pre-diabetes, or diabetes.

[0125] In another embodiment, the present disclosure provides a method for improving or maintaining cognitive function. The cognitive function can be selected from the group consisting of perception, memory, attention, language comprehension, language expression, reading comprehension, imagery, learning, reasoning, and combinations thereof. In one embodiment, the individual does not have a cognitive disorder. The individual can be elderly.

[0126] In another embodiment, the present disclosure provides a method for enhancing at least one of cognitive performance or muscle performance. The combination can enhance cognitive performance, including memory. The combination can enhance muscle performance, including at least one of strength, speed, or endurance. The individual can be elderly.

[0127] In another embodiment, the present disclosure provides a method for the treatment of an injury, disease, or condition, comprising: (i) reducing the severity and / or incidence of the effects of aging; (ii) maintaining or improving cellular function and / or overall health; (iii) supporting at least one of normal mitochondrial function, cytoprotection, or energy metabolism; (iv) increasing daily energy levels; (v) reducing fatigue; (vi) maintaining or improving physical energy; (vii) promoting healthy aging by promoting health or normal cellular function; (viii) supporting healthy skin; (ix) treating heart failure and / or reducing the severity or incidence of heart failure; (x) treating, reducing the incidence, or reducing the severity of oxidative stress and / or reduced glutathione (GSH) during periods including intensive care unit (ICU) admission; (xi) treating, reducing the incidence, or reducing the severity of another condition associated with oxidative stress and / or reduced GSH; (xii) rehabilitation from injury, illness, or surgery (post-surgery, stroke, etc.) for improved functional performance (exercise tolerance, muscle contraction, fatigue). (xiii) regulating NAD+ levels in patients with cancer or in remission from cancer; (xiv) treating, reducing the incidence, or reducing the severity of symptoms resulting from bariatric surgery; (xv) treating, reducing the incidence, or reducing the severity of non-alcoholic fatty liver disease (NAFLD); (xvi) treating, reducing the incidence, or reducing the severity of human immunodeficiency virus infection (HIV); and (xvii) combinations thereof.

[0128] Another aspect of the disclosure is a method of preventing at least one of these conditions, comprising administering to an individual at risk for at least one of the conditions a composition comprising a prophylactically effective amount of a combination of at least one glycine or a functional derivative thereof and at least one large neutral amino acid and / or cationic amino acid or precursors thereof.

[0129] In one embodiment of these methods, the hyperlipidemia treated or prevented comprises hypertriglyceridemia. In one embodiment of these methods, the hyperlipidemia treated or prevented comprises an increase in free fatty acids. In one embodiment of these methods, the age-related neuronal cell death or dysfunction treated or prevented is by administration of the composition to a middle-aged or elderly individual, e.g., an elderly individual with sarcopenia.

[0130] Another aspect of the present disclosure is a method of delaying the onset of metabolic decline, maintaining muscle mass, reducing oxidative stress, maintaining immune function, and / or maintaining cognitive function in healthy middle-aged and older adults.

[0131] In one embodiment, the metabolic decline is oxidative damage in fatty liver.

[0132] Another aspect of the present disclosure is a method for improving mitochondrial function in an individual with sarcopenia, comprising administering to the individual an effective amount of a combination of at least one glycine or a functional derivative thereof and at least one large neutral amino acid and / or cationic amino acid or precursor thereof.

[0133] Yet another aspect of the present disclosure is a method of enhancing reactive oxygen species metabolism, improving glucose regulation, and / or improving muscle function in an individual having at least one of obesity, pre-diabetes, or diabetes.

[0134] Another aspect of the present disclosure is a composition comprising a combination of at least one glycine or a functional derivative thereof and at least one large neutral amino acid and / or cationic amino acid or precursors thereof in a total amount effective to improve at least one of muscle performance or cognitive performance (e.g., memory). In a related embodiment, a method of improving at least one of muscle performance or cognitive performance (e.g., memory) of an individual comprises administering to the individual a composition comprising an effective amount of at least one glycine or a functional derivative thereof and at least one large neutral amino acid and / or cationic amino acid or precursors thereof.

[0135] Furthermore, with respect to muscle performance, the improvement in muscle performance may be one or more of improved muscle function, reduced decline in muscle function, improved muscle strength, improved muscle endurance, and improved muscle recovery. The composition can improve physical endurance (e.g., the ability to perform physical tasks such as exercise, physical labor, sports activities, etc.), inhibit or delay physical fatigue, improve blood oxygen levels, improve energy in healthy individuals, improve work capacity and endurance, reduce muscle fatigue, reduce stress, enhance cardiovascular function, improve sexual performance, increase muscle ATP levels, and / or reduce blood lactate. "Endurance" refers to the time to fatigue when exercising at a given workload, typically at an intensity <80% VO2max. In some embodiments, the composition is administered in an amount that increases mitochondrial activity, increases mitochondrial biogenesis, and / or increases mitochondrial mass.

[0136] In some embodiments, the composition is administered to an individual with reduced physical performance, reduced endurance, and / or reduced muscle function. Improved muscle function may be particularly effective in elderly subjects with reduced muscle function as a result of age-related conditions. For example, subjects who may experience reduced muscle function that may later lead to pre-frailty and frailty may benefit from improved muscle function. Such subjects do not necessarily experience muscle wasting in conjunction with reduced muscle function. Some subjects, such as those with sarcopenia, experience both muscle wasting and reduced muscle function. The composition may enhance muscle performance in frail or pre-frail subjects.

[0137] Sports performance refers to the ability of an athlete's muscles to perform when participating in a sports activity. Enhanced sports performance, strength, speed, and endurance are measured by increasing the strength of muscle contraction, increasing the amplitude of muscle contraction, or shortening the muscle reaction time between stimulation and contraction. An "athlete" refers to an individual who participates in sports at any level and aims to improve strength, speed, or endurance in their performance, such as bodybuilders, cyclists, long-distance runners, and sprinters. Enhanced sports performance is manifested as the ability to overcome muscle fatigue, maintain activity for longer periods of time, and perform more effective workouts.

[0138] The compositions and methods disclosed herein may also be effective in treating muscle-related pathological conditions, including myopathies; neuromuscular diseases such as Duchenne muscular dystrophy; acute sarcopenia, e.g., muscle atrophy; and / or cachexia associated with burns, bed rest, limb immobilization, or major thoracic, abdominal, and / or orthopedic surgery.

[0139] The compositions may treat or prevent sarcopenia, sarcopenic obesity, or cachexia, such as cachexia due to an underlying medical condition, such as chronic disease, HIV, cancer, chronic obstructive pulmonary disease (COPD), and / or aging, in otherwise healthy individuals. In this regard, aging is associated with a decline in NAD+ This may be accompanied by a decrease in insulin and glutathione (GSH).

[0140] The compositions can treat or prevent eye conditions that result directly or indirectly from low GSH concentrations, such as low concentrations in the lens where glutathione is known to be present in high concentrations. Non-limiting examples of such conditions include cataracts and / or glaucoma, presbyopia (age-related loss of near vision that requires magnifying glasses), and presbycusis (age-related loss of hearing that requires hearing aids).

[0141] In one embodiment, the composition improves at least one of muscle performance or muscle recovery from muscle tone, including muscle tone associated with exercise. The exercise may be of any type, including, for example, aerobic exercise (cardio exercise) and / or weight training. The composition may be administered during at least one period selected from the group consisting of before exercise (e.g., within less than one hour before exercise), during exercise, and after exercise (e.g., within less than one hour after exercise).

[0142] A further aspect of the present disclosure is a composition comprising at least one glycine or functional derivative thereof in combination with at least one large neutral amino acid and / or cationic amino acid or precursors thereof in an amount effective to improve or maintain at least one of mitochondrial function or metabolic rate. In a related embodiment, a method of improving or maintaining at least one of mitochondrial function or metabolic rate in an individual comprises administering to the individual a composition comprising at least one glycine or functional derivative thereof in combination with at least one large neutral amino acid and / or cationic amino acid or precursors thereof in an effective amount.

[0143] Another aspect of the disclosure is a composition comprising at least one glycine or functional derivative thereof in combination with at least one large neutral amino acid and / or cationic amino acid or precursors thereof in a total amount effective to improve or maintain cognitive function. In a related embodiment, a method of improving or maintaining cognitive function in an individual comprises administering to the individual a composition comprising at least one glycine or functional derivative thereof in combination with at least one large neutral amino acid and / or cationic amino acid or precursors thereof in a prophylactically effective amount.

[0144] In one embodiment, the individual does not have a cognitive disorder, for example, the composition can enhance cognitive function in a subject with normal cognitive function.

[0145] The compositions disclosed herein can also be used to treat any of a variety of additional diseases and conditions in which defective or reduced mitochondrial activity is involved in the pathophysiology of the disease or condition, or in which increased mitochondrial function provides a desired beneficial effect.

[0146] Method for producing the nutritional composition of the present invention The present invention relates in a further aspect to a method for producing a nutritional composition for use according to the invention, comprising the steps of: The present invention relates to a method comprising the steps of preparing raw materials for a nutritional composition comprising a combination of oleuropein and / or its metabolites and quercetin and / or its derivatives, and mixing the raw materials so that the nutritional composition comprises a combination of oleuropein and / or its metabolites and quercetin and / or its derivatives.

[0147] Disclosure Combinations It should be noted that embodiments and features described in the context of one aspect of the invention also apply to other aspects of the invention.

[0148] Compositions for use according to the invention are described herein under different parameters, such as ingredients, form of nutritional composition, use, target population, etc. It should be noted that embodiments and features described in the context of one of the parameters of a composition for use according to the invention may also be combined with other embodiments and features described in the context of another parameter, unless expressly stated otherwise.

[0149] All patent and non-patent literature cited in this application is hereby incorporated by reference in its entirety.

[0150] The invention will now be described in further detail by the following non-limiting examples. EXAMPLES

[0151] The following non-limiting examples provide experimental data supporting the compositions and methods disclosed herein.

[0152] Example 1 Zebrafish study Materials and Methods Zebrafish breeding and transgenic line generation Adult AB zebrafish were kept at 28°C under standard housing conditions. All experimental procedures were performed in accordance with Swiss and EU ethical guidelines and approved by the Vaud cantonal ethical committee for animal experiments (permit VD3177). Constructs containing zebrafish ppargc1a or human PPARGC1A cDNA fused to a triple Flag sequence under the control of the skeletal muscle-specific actc1b promoter were inserted by I-SCEI meganuclease into one-cell stage AB embryos to generate transgenic zebrafish. The injected constructs carried an eye marker cassette carrying ZsGreen under the control of the inverted cryaa (alpha crystallin A chain) promoter for rapid selection of transgenic animals. Transgenic carriers were outcrossed with AB zebrafish to generate transgenic and wild-type siblings.

[0153] Oxyblot Carbonylated proteins were measured in frozen skeletal muscle using the Oxidized Protein Detection Kit (Abcam, #ab178020) according to the manufacturer's instructions. Quantification of oxidized proteins was performed by processing and analyzing oxidized blots using ImageJ (1.51h, NIH).

[0154] RNA-seq and analysis For gene expression analysis, flash frozen skeletal muscle was dissolved in Qiazol using a FastPrep®-24 tissue homogenizer (MP-Biomedials). Total mRNA was extracted using the QIAcube platform (plateform) and the mRNAeasy kit (Qiagen). RNA was quantified using Ribogreen (Life Technologies) and quality was assessed with a Fragment Analyzer (Advances Analytical). Sequencing libraries were prepared from 250 ng of RNA using the TruSeq Stranded mRNA LT Sample Prep Kit (Illumina) according to the manufacturer's protocol, except for the PCR amplification step, which was performed for 15 cycles using KAPA HiFi HotStart ReadyMix (Kapa BioSystems). The optimal number of PCR cycles was evaluated using the cycler correction factor method as previously published (Atger et al., Proc Natl Acad Sci USA. 2015 Nov 24;112(47):E6579-88). Libraries were quantified with Picogreen (Life Technologies). Size patterns were controlled using a DNA high sensitivity reagent kit on a LabChip GX (Perkin Elmer). Libraries were pooled and the pools were then quantified using 2 *Clustering was performed at a concentration of 9 pmol on an 8-lane paired-end sequencing high output flow cell (Illumina). Sequencing was performed on a HiSeq 2500 using v4 SBS chemistry for 2 × 125 cycles as recommended by Illumina.

[0155] Image analysis and base calling were performed using Illumina Real-Time Analysis. Raw data are available at (Accession no. #). Paired-end reads were mapped onto the zebrafish GRCz10 reference genome using STAR 2.4.0i (Dobin et al., Bioinformatics 2013 Jan 1;29(1):15-21). Uniquely mapped reads were counted for each gene using Python Package HTseq 0.9.1 (Anders et al., Bioinformatics.2015 Jan 15;31(2):166-9) to calculate transcript expression levels. Read count normalization and differential expression analysis were performed using Bioconductor 3.6 Package DESeq2 (Love et al., Genome Biol.2014;15(12):550). Genes with adjusted p-values ​​<0.05 and log2 fold changes >0.5 were used to compare genotype- or exercise-induced expression.

[0156] Gene Ontology (GO) analysis was performed using DAVID Bioinformatics Resources 6.8 (Dennis et al., Genome Biol. 2003;4(5):P3). KEGG pathway annotations were used for enrichment testing. Categories with a P value of less than 0.05 were considered significantly enriched.

[0157] Acute oxidative stress and high-resolution mitochondrial respiration measurements Adult AB zebrafish, aged 4–6 months, were exposed to acute oxidative stress for 2 h at 28°C in water supplemented with 3 μM menandione (Sigma-Aldrich). After stress, the fish were divided into control and treatment groups. The oxidative stress control group was then incubated for 2 h at 28°C in purified water. Zebrafish exposed to glycine and glucose treatments were incubated for 2 h at 28°C in water containing the compounds of interest at the following doses: glycine, 50 μM, 200 μM, and 450 μM (Sigma-Aldrich); glucose, 500 μM and 5 mM (Sigma-Aldrich). Crude mitochondrial extracts were prepared from zebrafish trunk muscle using a methodology slightly modified as previously described (Frezza et al., Nat Protoc. 2007;2(2):287-95). After quantification of protein concentration by BCA, 150 μg of crude extract was used for quantification by high-resolution respirometry. An Oxygraph-2k (O2k, OROBOROS Instruments) was used for respiration measurements. Up to three O2k devices (5 chambers) were used simultaneously. Experiments were performed at 28 °C in a modified MiR05 (110 mM sucrose, 0.5 mM EGTA, 3 mM MgCl2, 20 mM taurine, 10 mM KH2PO4, 20 mM HEPES, and 0.1% BSA, essentially fatty acid free). Respiration of isolated mitochondria was measured using a modified substrate-uncoupler-inhibitor titration (SUIT) protocol (Pesta and Gnaiger, Methods Mol Biol. 2012;810:25-58). Complex I (CI) respiration was induced in the presence of ADP (1 mM) using pyruvate, glutamate, and malate (5 mM, 10 mM, 2 mM, respectively) as substrates. Complex II (CII) respiration was induced by adding succinate (10 mM) in the presence of ADP. CI respiration was calculated as the difference between total respiration (CI + CII) and addition of the CI inhibitor rotenone (0.5 μM). CII respiration was calculated as the difference between inhibited CI respiration and addition of the CII inhibitor malonate (5 mM). Total respiration (CI + CII, Tot respiration) was assessed as the difference between respiration in the presence of all substrates and the sum of inhibition of CI and CII.

[0158] result PGC1α is a key regulator of mitochondrial biogenesis. We have created a zebrafish transgenic model that overexpresses PGC1α protein in muscle, resulting in mass production of mitochondria. While an increase in the number of mitochondria is thought to be beneficial because it improves the cellular energy availability, it also leads to increased production of ROS and oxidative stress that worsens during aging (Figure 1, protein carbonylation is a marker of oxidative damage).

[0159] We then performed gene expression analyses on immature PGC1α zebrafish and wild-type exercised zebrafish ("trained wild-type") to compare a more physiological model of mitochondrial biogenesis induction with genetic overexpression. We found that zebrafish overproducing mitochondria have enhanced pathways for branched-chain amino acid catabolism (Table 1), and similar to habitually exercised zebrafish, naturally increasing mitochondria have enhanced amino acid transport (Figure 2).

[0160] [Table 1]

[0161] In particular, cationic amino acid transporters (SLC7A1) and large neutral amino acid transporters (SLC43A1a, ​​SLC43A1b, SLC3A2, SLC3A2a, SLC3A2b) were overexpressed, suggesting that these amino acids are required even more to maintain mitochondrial function during high oxidative stress (Figure 2). Furthermore, we know from previous in-house studies that glycine can restore mitochondrial respiration after acute oxidative stress. In Figure 3, acute oxidative stress is induced with a short period of menadione treatment (Men), which reduces complex I-dependent respiration. Treatment with glycine restores the levels of complex I respiration, while treatment with glucose does not show any effect. These results support the hypothesis that oxidative stress reduces O2 flux in mitochondria by blocking glycolytic enzymes. This blockade reduces substrate availability for the TCA cycle to support the respiratory chain. In these conditions, our data suggest that amino acids are used to feed the TCA cycle and restore energy imbalance.

[0162] These preliminary results suggest that a combination of glycine with cationic and large neutral amino acids may help mitochondria maintain good functionality in conditions of high oxidative stress, such as aging, exercise, musculoskeletal disorders, respiratory disorders, pain syndromes, neurodegenerative or metabolic diseases.

[0163] Example 2: Studies in dogs and cats Metabolomic analysis Venous blood samples were collected from dogs with and without mitral valve disease (MVD) and from cats with and without chronic kidney disease (CKD). Blood was allowed to clot and centrifuged at 1600 g for 5 minutes to obtain serum samples, which were stored at -80°C until use.

[0164] Untargeted metabolomics assays were performed in a commercial laboratory (Metabolon, Inc.). Samples were prepared using an automated MicroLab STAR® system from Hamilton. For QC purposes, multiple recovery standards were added before the first step in the extraction process. To remove proteins, dissociate small molecules bound to proteins or trapped in the precipitated protein matrix, and recover chemically diverse metabolites, proteins were precipitated with methanol (Glen Mills GenoGrinder 2000) with vigorous shaking for 2 min, followed by centrifugation. The resulting extract was divided into five fractions. Two samples were for analysis by two separate reversed-phase (RP) / UPLC-MS / MS methods with positive ion mode electrospray ionization (ESI), one sample was for analysis by RP / UPLC-MS / MS with negative ion mode ESI, one sample was for analysis by HILIC / UPLC-MS / MS with negative ion mode ESI, and one sample was saved for backup. Samples were briefly placed in a TurboVap® (Zymark) to remove the organic solvent. Sample extracts were stored under nitrogen overnight before preparation for analysis. (Compound detection and identification were performed using Metabolon proprietary software and databases. Further information regarding processing and analysis can be found in Li et al. JAHA 2021 (https: / / doi.org / 10.1161 / JAHA.120.018923).

[0165] Raw data were generated based on area under the curve equations using ion counts, which provides relative quantification. Metabolites with missing values ​​in >80% of samples were excluded. Under the assumption that missing data were below the detection limit, the remaining missing data were imputed a value equivalent to half of the minimal value of the raw data. Metabolites that included the lower 25th percentile of the interquartile range showed nearly constant values ​​and were excluded. Data were further transformed using log base 2 and autoscaled to achieve zero mean and unit variance for all metabolites. ANOVA was performed to compare means between MVD groups in dogs or CKD groups in cats.

[0166] Dogs with MVD had lower serum concentrations of glutamine, glycine, and methionine compared to non-MVD dogs (Table 2). Concentrations of the glycine derivative sarcosine were decreased in dogs with congestive heart failure (stage C or stage D) compared to healthy dogs or dogs with asymptomatic MVD (stages B1 and B2). Similarly, serum concentrations of methionine, glycine, glutamate, glutamine, serine, and cysteine ​​were lower in cats with CKD compared to non-CKD cats (Table 3). Sarcosine levels were lower in cats with advanced CKD (i.e., stage 3 or stage 4) compared to non-CKD cats or cats with early CKD (i.e., stage 1 or stage 2). This data suggests a deficiency of these amino acids in dogs with cardiac disease and cats with renal disease. Supplementation of these amino acids would improve the health of dogs and cats with cardiac and renal disease.

[0167] [Table 2]

[0168] [Table 3]

[0169] Example 3 Testing of Amino Acid Blends To evaluate the health benefits in kidneys, an amino acid blend was tested using HK2 cell responses. The amino acid blend consisted of glycine, methionine, cysteine, and glutamine. The protocol for the luminescent cell viability assay by measuring ATP, a key indicator of cell health, is detailed below.

[0170] For each experiment, frozen stocks of HK2 cells banked at less than passage 4 were thawed and grown in regular growth medium at 37°C and 5% CO in a humidified incubator. HK2 cells were cultured for up to three passages prior to cell assays and were passaged approximately every 3 days when they reached 70-80% confluency.

[0171] 2500 HK2 cells were seeded in regular growth medium in 384-well plates. After 24 hours, the cells were starved for 2 hours in HBSS buffer to remove all trace amino acids, and then fresh medium was added with a specific combination of either control medium containing all amino acids, medium without amino acids, medium containing a blend of 4 amino acids, medium containing all amino acids except the 4 amino acids of interest, medium containing only glycine, medium containing only methionine, medium containing only cysteine, medium containing only glutamine, and medium containing only cysteine ​​+ glutamine, and incubated for 48 hours.

[0172] The treatment was stopped by adding CellTiter-Glo® 2.0 assay reagent from Promega, cells were lysed, and after 20 minutes of incubation at room temperature with gentle shaking, luminescence levels were measured using a luminescence plate reader as an indicator of cell viability. The presence of ATP indicates the presence of metabolically active cells.

[0173] result The results for cell viability are shown in Table 4, where "control" is regular growth medium containing all amino acids, "w / o aa" is regular growth medium without any amino acids, "-4 aa" is regular growth medium containing all amino acids except the amino acid blend (glycine, methionine, cysteine, and glutamine), and "+4 aa" is regular growth medium containing only the amino acid blend.

[0174] [Table 4]

[0175] In the absence of amino acids, viability is reduced by approximately 70%, as is the case for all amino acids except the 4 amino acid blend. The 4 amino acid blend alone protects against cell death at approximately 80% of the control level. The data suggest that the 4aa blend, which contains glycine, cysteine, glutamine, and methionine, plays an essential role in maintaining tubule cell proliferation and survival to support cell health. Additional studies were performed to investigate the 4 amino acid blend. The results are shown in Table 5.

[0176] [Table 5]

[0177] Of note, Table 5 shows the unexpected result that glutamine works similarly to the blend, but glutamine and cysteine ​​in combination provide no protective effect, and therefore cannot explain their effects alone. Thus, the performance of the blend predicted based on the effects of glycine and methionine individually, and glutamine and cysteine ​​combined, is significantly lower (about 80% of control) than the blend actually works (about 99% of control). This is unexpected and suggests a synergistic effect of the four-component blend.

[0178] It should be understood that various changes and modifications to the presently preferred embodiments described herein will be apparent to those skilled in the art. Such changes and modifications can be made without departing from the spirit and scope of the present subject matter and without diminishing its intended advantages. Accordingly, such changes and modifications are intended to be encompassed by the appended claims.

Claims

1. 1. A composition comprising a synergistic blend of amino acids for providing a health benefit to an animal, said blend comprising a combination of glycine, methionine, cysteine ​​and glutamine.

2. 2. The composition of claim 1, wherein the composition treats or prevents a disease or condition selected from the group consisting of stress, obesity, reduced metabolic rate, metabolic syndrome, diabetes mellitus, diabetic complications, cardiovascular disease, hyperlipidemia, respiratory disease, pain syndrome, neurodegenerative disease, cognitive impairment, stress-induced or stress-related cognitive dysfunction, mood disorder, anxiety disorder, age-related neuronal cell death or dysfunction, musculoskeletal disorder, sarcopenia, frailty, pre-frailty, chronic kidney disease, renal disease, macular degeneration, and combinations thereof.

3. 10. The composition of claim 1, wherein the composition treats or prevents a disease or condition selected from the group consisting of adverse effects of aging, muscle loss, prediabetes, gestational diabetes, type I diabetes, type II diabetes, diabetic complications, insulin resistance, metabolic syndrome, dyslipidemia, elevated cholesterol levels, elevated triglycerides levels, elevated fatty acids levels, fatty liver disease, musculoskeletal diseases, respiratory diseases, pain syndromes, neurodegenerative diseases, cognitive impairment, myopathy such as statin-induced myopathy, non-alcoholic steatohepatitis, tinnitus, dizziness, alcohol hangover, hearing loss, osteoporosis, high blood pressure, atherosclerosis / coronary artery disease, myocardial injury after stress, traumatic brain injury, cystic fibrosis, inflammation, cancer, and HIV infection.

4. The glycine is L-glycine, L-glycine ethyl ester, D-allylglycine, N-[bis(methylthio)methylene]glycine methyl ester, Boc-allyl-Gly-OH (dicyclohexylammonium) salt, Boc-D-Chg-OH, Boc-Chg-OH, (R)-N-Boc-(2'-chlorophenyl)glycine, Boc-L-cyclopropylglycine, Boc-L-cyclopropylglycine, (R)-N-Boc-4-fluorophenylglycine, Boc-D-propargylglycine, Boc-(S)-3-thien ...

2. The composition of claim 1, wherein the glycine is selected from the group consisting of oc-(R)-3-thienylglycine, D-a-cyclohexylglycine, L-a-cyclopropylglycine, N-(2-fluorophenyl)-N-(methylsulfonyl)glycine, N-(4-fluorophenyl)-N-(methylsulfonyl)glycine, Fmoc-N-(2,4-dimethoxybenzyl)-Gly-OH, N-(2-furoyl)glycine, L-a-neopentylglycine, D-propargylglycine, sarcosine, Z-a-phosphonoglycine trimethyl ester, and mixtures thereof.

5. 2. The composition of claim 1, wherein the animal is a cat and the glycine is present in an amount of about 1% to about 15% by weight when fed, or the animal is a dog and the glycine is present in an amount of about 0.5% to about 15% by weight when fed.

6. 2. The composition of claim 1, wherein the animal is a cat and the methionine is present in an amount of about 0.2% to about 1.5% by weight when fed, or the animal is a dog and the methionine is present in an amount of about 0.33% to about 5% by weight when fed.

7. 2. The composition of claim 1, wherein the animal is a cat and the cysteine ​​is present in an amount of about 0.2% to about 10% by weight when fed, or the animal is a dog and the cysteine ​​is present in an amount of about 0.1% to about 10% by weight when fed.

8. 2. The composition of claim 1, wherein the animal is a cat and the glutamine is present in an amount of about 2% to about 30% by weight when fed, or the animal is a dog and the glutamine is present in an amount of about 1% to about 30% by weight when fed.

9. 10. The composition of claim 1, further comprising fat, protein, carbohydrates, and fiber.

10. 10. The composition of claim 9, wherein the protein comprises collagen, whey, or a mixture thereof.

11. The composition of claim 1 , wherein the composition is selected from the group consisting of a pet food product, a supplement, and a treat.

12. 1. A method of providing a health benefit to an animal, comprising administering to said animal a synergistic blend of amino acids, said blend comprising a combination of glycine, methionine, cysteine ​​and glutamine.

13. 13. The method of claim 12, wherein the administration is periodic and the animal is a companion animal.

14. 13. The method of claim 12, wherein the blend can be administered to a cat to provide a daily dose of about 125 mg to about 1.5 g glycine per kg bw, about 25 mg to about 1 g cysteine ​​per kg bw, about 250 mg to about 5 g glutamine (and / or glutamate) per kg bw, and about 25 mg to about 500 mg methionine per kg bw; or, the blend can be administered to a dog to provide a daily dose of about 70 mg to about 2.25 g glycine per kg bw, about 14 mg to about 1.5 g cysteine ​​per kg bw, about 140 mg to about 4.5 g glutamine (and / or glutamate) per kg bw, and about 46 mg to about 750 mg methionine per kg bw.

15. The composition is intended to treat stress, obesity, reduced metabolic rate, metabolic syndrome, diabetes mellitus, diabetic complications, cardiovascular disease, hyperlipidemia, respiratory disease, pain syndrome, neurodegenerative disease, cognitive impairment, stress-induced or stress-related cognitive dysfunction, mood disorder, anxiety disorder, age-related neuronal cell death or dysfunction, musculoskeletal disorder, sarcopenia, frailty, pre-frailty, chronic kidney disease, kidney disease, macular degeneration, adverse effects of aging, muscle loss, pre-diabetes, gestational diabetes, type I diabetes, type II diabetes, diabetic complications, insulin resistance, metabolic syndrome, 13. The method of claim 12, wherein the method is for treating or preventing a disease or condition selected from the group consisting of: cardiovascular disease, cardiovascular disease, pulmonary edema, dyslipidemia, elevated cholesterol levels, elevated triglycerides, elevated fatty acids, fatty liver disease, musculoskeletal disease, cognitive impairment, myopathy such as statin-induced myopathy, non-alcoholic steatohepatitis, tinnitus, dizziness, alcohol hangover, hearing loss, osteoporosis, high blood pressure, atherosclerosis / coronary artery disease, myocardial injury after stress, traumatic brain injury, cystic fibrosis, inflammation, cancer, and HIV infection.

Citation Information

Patent Citations

  • Compositions and methods for improving kidney function

    JP2008525529A

  • Tube feed formulation and methods for using the same

    JP2018183158A

  • Methods and Compositions Using Fresh or Frozen Meat to Improve Feed Efficiency in Animals Such as Dogs

    JP2018512843A

  • Effects of supplementation with n-acetylcysteine and glycine to improve glutathione levels

    JP2021073181A

  • Glutamine for preserving, improving or restoring kidney function

    US20190183961A1